Skip to main content
Reading Time: 4 minutes

Navigating the ADHD Medication Shortage: Challenges and Impacts

There may be light at the end of the tunnel for people impacted by the Attention Deficit Hyperactivity Disorder (ADHD) medication shortage. This has been of public concern since October 2022, when the United States Food & Drug Administration (FDA) announced a shortage of the immediate-release formulation of amphetamine mixed salts, commonly known as Adderall (amphetamine/destroamphetamine). In addition to Adderall, other ADHD drugs, like variations of methylphenidate (e.g., Ritalin or Concerta), have been affected by shortages since May 2023.

What is ADHD?

ADHD is a neurodevelopmental condition that affects both children and adults and is characterized by a pattern of persistent inattention, hyperactivity, and impulsivity that interferes with daily functioning or development. Inattentive symptoms of ADHD may include difficulty sustaining attention, being easily distracted, forgetfulness, and having trouble organizing tasks or activities. Hyperactive and impulsive symptoms may manifest as restlessness, fidgeting, excessive talking, and difficulty waiting one’s turn. It’s important to note that ADHD is not just a matter of being easily distracted or hyperactive occasionally; it is a chronic condition that can significantly impact various aspects of life, including academic performance, relationships, and self-esteem.

Although the exact cause of ADHD is not fully understood, research suggests that both genetic and environmental factors contribute to its development. Brain imaging studies have shown differences in brain structure and activity in individuals with ADHD, particularly in regions responsible for attention, impulse control, and executive functions. ADHD is typically diagnosed based on specific criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM). The diagnosis involves assessing the presence and severity of symptoms, ruling out other possible causes, and considering the duration and impact of these symptoms on daily life.

Treatments For ADHD

Treatment for ADHD often involves a multimodal approach, combining medication, behavioral therapy, and educational or workplace accommodations. The most common types of medications used to manage ADHD symptoms fall into two categories: stimulant medications, such as methylphenidate-based drugs (e.g., Ritalin), and amphetamines (e.g., Adderall), and non-stimulant medications, like atomoxetine (e.g., Strattera). Stimulant medications are the most commonly prescribed for ADHD and are considered the first-line treatment. They work by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which play a role in attention and focus. Non-Stimulant Medications are used when stimulant medications are not well-tolerated or when there are specific concerns about using stimulants. They work differently from stimulants but still help manage ADHD symptoms. Common medications for ADHD include:

Medication Class Drug name Brand Name Largest Manufacturer FDA Approval Year
Stimulant Based Methylphenidate -based Ritalin Novartis 1955
Concerta Janssen 2000
Daytrana Noven 2006
Metadate Lannett 2001
Quillivant XR Pfizer/Tris 2012
Amphetamine-Based Adderall Teva 1996
Dexedrine Teva 2001
Vyvanse Teva 2007
Non-Stimulant Based Norepinephrine reuptake inhibitor (NRI) Strattera Eli Lilly 2002
Alpha-2 Adreneergic Agonist Intuniv Takeda 2009
Kapvay Shionogi 2010


It’s essential to note that the choice of medication and the treatment plan is individualized for each patient. People may respond differently to various medications, and the right medication and dosage are determined based on factors such as age, specific symptoms, medical history, and individual response to the drug. Regular follow-up with a healthcare provider is crucial to monitor the effectiveness and safety of the treatment and make any necessary adjustments.

Additionally, behavioral therapies and other non-pharmacological interventions are often combined with medication to manage ADHD more effectively. Behavioral therapy aims to teach individuals coping strategies, time management, and organizational skills, which can improve focus and self-control. Supportive counseling can help address the emotional and social challenges associated with the disorder.

While ADHD can present challenges, many individuals with the condition have unique strengths, such as creativity, hyperfocus on certain tasks, and out-of-the-box thinking. With proper diagnosis and treatment, individuals diagnosed with ADHD can lead successful and fulfilling lives. Early intervention and ongoing support can make a significant difference in managing symptoms and maximizing potential.

ADHD Medications Currently in Shortage

The FDA has reported a shortage of the following ADHD medications and their estimated availability:

  • Methylphenidate Hydrochloride Extended-Release Tablets (mid-to-end-August 2023)
  • Amphetamine Mixed Salts (September-December 2023)
  • Guanfacine Hydrochloride (TBD)

Potential Causes of the ADHD Medication Shortage

The scarcity has caused frustration and uncertainty for millions of patients who rely on these drugs. The increased demand for medication during the COVID-19 pandemic, manufacturing issues, and supply chain disruptions led to shortages. Studies show patients’ increasing need for these medications, particularly during the COVID-19 pandemic, where remote work and disrupted routines may have contributed to ADHD symptom exacerbation and an uptick in ADHD diagnosis.

The reasons for the shortage may also include relaxed regulations during the COVID-19 pandemic. Before the pandemic, the Drug Enforcement Administration (DEA) required an in-person visit to prescribe controlled substances like ADHD medications via telehealth. However, during the public health emergency, the rules were loosened to ensure that patients could still access their medications even when in-person doctor appointments were limited. The relaxed regulations made it easier for people to receive prescriptions for ADHD medications through telemedicine without an initial in-person visit to the doctor.

Implications of The ADHD Medication Shortage

The shortage has caused difficulties for patients who rely on these medications to manage their ADHD symptoms. Individuals with ADHD who temporarily discontinue their medication may experience worsened distractibility, procrastination, and reduced productivity. This can negatively affect their personal and professional lives, leading to conflicts at work or home. Long-term discontinuation of ADHD medications may have more dire consequences, including returning ADHD symptoms, impaired performance, emotional and behavioral changes, impaired executive functioning, reduced quality of life, academic/occupational challenges, and increased risk-taking behavior.


ADHD patients face challenges filling prescriptions, with some turning to alternative, intermittently available medications. ADHD patients and their caregivers are encouraged to cope with the shortage by establishing a relationship with their local pharmacies, considering alternative medications, and exploring non-drug treatments and lifestyle management strategies for ADHD. Resolving these shortages is further complicated due to strict regulations surrounding ADHD medications, which are classified as Schedule II controlled substances.

While there are signs of improvement in medication access in some areas, the shortage remains a concern for patients with ADHD who depend on these medications to manage their symptoms effectively. As pharmaceutical companies report limited availability of various ADHD medications, the FDA continues to monitor the situation. With optimism, certain companies anticipate the restoration of supplies in 2023.


Vita Maziveyi, PhD

Senior Medical Writer

Cadence Communications & Research

August 2023



Author Vita Maziveyi

Vita Maziveyi is a Senior Medical Writer at Cadence Communications & Research, where she leverages over 10 years of oncology research expertise and 3 years in drug discovery to contribute to the Medical Communications team. Previously, she led the development of at-home diagnostic tests as the Science Development Lead at Hurdle and managed genetic test development and marketing as a Key Account Manager at Gene By Gene. With a Ph.D. in Biochemistry and Molecular Biology from the Louisiana State University Health Sciences Center New Orleans and a Postdoctoral Research Fellowship from the University of Texas Southwestern Medical Center, Vita's career is marked by a commitment to advancing medical science and improving patient outcomes.

More posts by Vita Maziveyi